{"id":"placebo-to-vorinostat","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"},{"rate":"20-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL98","moleculeType":"Small molecule","molecularWeight":"264.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This results in the inhibition of cell growth and induction of apoptosis in cancer cells. Vorinostat also has anti-inflammatory properties and can modulate the immune response.","oneSentence":"Vorinostat is a histone deacetylase inhibitor that works by blocking the action of histone deacetylases, leading to the accumulation of acetylated histones and altered gene expression.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:57.439Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cutaneous T-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT00616967","phase":"PHASE2","title":"Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2008-05","conditions":"Breast Cancer","enrollment":68},{"nctId":"NCT01413750","phase":"PHASE2","title":"Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11-08","conditions":"Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7","enrollment":23},{"nctId":"NCT03263533","phase":"EARLY_PHASE1","title":"HDAC Inhibitor Augmentation to Clozapine","status":"WITHDRAWN","sponsor":"Virginia Commonwealth University","startDate":"2017-04","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT00773747","phase":"PHASE3","title":"Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-12-01","conditions":"Multiple Myeloma","enrollment":637},{"nctId":"NCT00632931","phase":"PHASE1","title":"A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-07","conditions":"Advanced Cancer Relapsed, Advanced Cancer Refractory","enrollment":25},{"nctId":"NCT00473889","phase":"PHASE2, PHASE3","title":"A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-05","conditions":"Stage IIIB or IV Non-Small Cell Lung Cancer","enrollment":253},{"nctId":"NCT00481078","phase":"PHASE2","title":"Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":94},{"nctId":"NCT01600742","phase":"PHASE2","title":"Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2012-08","conditions":"Brain Metastasis","enrollment":4},{"nctId":"NCT01353482","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma","status":"WITHDRAWN","sponsor":"University College, London","startDate":"","conditions":"Malignant Pleural Mesothelioma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo to vorinostat","genericName":"placebo to vorinostat","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vorinostat is a histone deacetylase inhibitor that works by blocking the action of histone deacetylases, leading to the accumulation of acetylated histones and altered gene expression. Used for Cutaneous T-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}